Efficacy and Safety of DCAG Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia
10.19746/j.cnki.issn1009-2137.2025.01.002
- VernacularTitle:DCAG方案治疗复发/难治性急性髓系白血病的疗效和安全性分析
- Author:
Hui-Sheng ZHOU
1
;
Yu-Qing LI
;
Yu-Xin WANG
;
Ya-Lei HU
;
Kai-Li MIN
;
Chun-Ji GAO
;
Dai-Hong LIU
;
Xiao-Ning GAO
Author Information
1. 解放军总医院第五医学中心血液病医学部,北京 100071;解放军医学院,北京 100853
- Publication Type:Journal Article
- Keywords:
relapsed;
refractory;
acute myeloid leukemia;
DCAG regimen
- From:
Journal of Experimental Hematology
2025;33(1):9-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of DCAG(decitabine,cytarabine,anthracyclines,and granulocyte colony-stimulating factor)regimen in the treatment of patients with relapsed/refractory(R/R)acute myeloid leukemia(AML).Methods:The clinical data of 64 R/R AML patients received treatment at Chinese PLA General Hospital from January 1st,2012 to December 31st,2022 were retrospectively analyzed.Primary endpoints included efficacy measured by overall response rate(ORR)and safety.Secondary endpoints included overall survival(OS),event-free survival(EFS)and duration of response(DOR).The patients were followed from enrollment until death,or the end of last follow-up(June 1st,2023),whichever occurred first.Results:Sixty-four patients who failed prior therapy were enrolled and completed 1 cycle,and 26 and 5 patients completed 2 and 3 cycles,respectively.Objective response rate was 67.2％[39:completeremission(CR)/CR with incomplete hematologic recovery(CRi),4:partial remission(PR)].With a median follow-up of 62.0 months(1.0-120.9),the median overall survival(OS)was 23.3 and event-free survival was 10.6 months.The median OS was 51.7 months(3.4-100.0)in responders(CR/CRi/PR)while it was 8.4 months(6.1-10.7)in nonresponders(P＜0.001).Grade 3-4 hematologic toxicities were observed in all patients.Four patients died from rapid disease progression within 8 weeks after chemotherapy.Conclusion:The DCAG regimen represents a feasible and effective treatment for R/R AML.
